Abiopharma

(99% Neutral) TherapeuticsMD, Inc. (TXMD) Announces Business Combination

(10% Negative) Ultragenyx Pharmaceutical Inc. (RARE) Announces Business Combination

(99% Neutral) Vir Biotechnology, Inc. (VIR) Announces Executive Changes

(99% Neutral) RUBIUS THERAPEUTICS, INC. (RUBY) Announces Clinical Development Update

(10% Negative) PACIRA BIOSCIENCES, INC. (PCRX) Announces Delay in sales Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment

(10% Negative) Marinus Pharmaceuticals, Inc. (MRNS) Announces Delay in voucher Trials for rare pediatric diseases Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process

(99% Neutral) THERAVANCE BIOPHARMA, INC. (TBPH) Announces Business Combination

(99% Neutral) INNOVIVA, INC. (INVA) Announces Business Combination

(99% Neutral) Ascendis Pharma (ASND) Announces Executive Changes (Form 6-K)

(19% Negative) THERAVANCE BIOPHARMA, INC. (TBPH) Announces Delay in units Trials for Potential Total Value ·Over $1 Due to Pandemic-Related Challenges, Regulatory Process